Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) plus binimetinib (bini) plus pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic BRAF V600-mutant melanoma
CANCER RESEARCH（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要